Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Pharmaceutical intermediates >  Heterocyclic compound >  Pyridine compound >  Hydroxypyridine >  5-NITRO-2-HYDROXY-4-METHOXYPYRIDINE

5-NITRO-2-HYDROXY-4-METHOXYPYRIDINE

Basic information Safety Supplier Related

5-NITRO-2-HYDROXY-4-METHOXYPYRIDINE Basic information

Product Name:
5-NITRO-2-HYDROXY-4-METHOXYPYRIDINE
Synonyms:
  • 4-Methoxy-5-nitro-1H-pyridin-2-one
  • 4-Methoxy-5-nitropyridin-2(1H)-one
  • 4-Methoxy-5-nitropyridin-2(1H)
  • 2-HYDROXY-4-METHOXY-5-NITROPYRIDINE
  • 5-NITRO-2-HYDROXY-4-METHOXYPYRIDINE
  • 2(1H)-Pyridinone,4-methoxy-5-nitro-(9CI)
  • 4-METHOXY-5-NITROPYRIDIN-2-OL
  • 2-Hydroxy-4-methoxy-5-nitropyridine ,98%
CAS:
607373-82-0
MF:
C6H6N2O4
MW:
170.12
Product Categories:
  • Building Blocks
  • Pyridine
  • METHOXY
Mol File:
607373-82-0.mol
More
Less

5-NITRO-2-HYDROXY-4-METHOXYPYRIDINE Chemical Properties

Melting point:
>161°C (dec.)
Boiling point:
345.7±42.0 °C(Predicted)
Density 
1.42±0.1 g/cm3(Predicted)
storage temp. 
Inert atmosphere,Room Temperature
solubility 
DMSO (Slightly), Methanol (Very Slightly)
pka
7.12±0.10(Predicted)
form 
Solid
color 
Dark Beige to Brown
More
Less

Safety Information

Hazard Codes 
Xi
HS Code 
2933399990
More
Less

5-NITRO-2-HYDROXY-4-METHOXYPYRIDINE Usage And Synthesis

Uses

2-Hydroxy-methoxy-5-nitropyridine is used in the preparation of Rho-Kinase inhibitors that display antihypertensive activity. Also it is used in the preparation of aminofurans as potent inhibitors of AKT kinase.

Synthesis

31872-62-5

607373-82-0

General procedure for the synthesis of 4-methoxy-5-nitropyridin-2(1H)-one from 4-methoxy-3-nitropyridine: 250 mL of anhydrous THF was added to a 1 L flask, cooled to -78 °C, and then concentrated NH3 (100-150 mL). Solid t-BuOK (200 mmol, 22.5 g) was added to THF and stirred vigorously for 10 min until completely dissolved. In another 500 mL flask, 4-methoxy-3-nitropyridine (12.3 g, 80 mmol) was dissolved in 100 mL of anhydrous THF and cooled to 0°C. To this solution was added t-BuOOH (88 mmol, 16 mL). The t-BuOOH/THF solution was then slowly added to an ammonia solution at -78 °C via a dropping funnel over 20 min. The reaction mixture was slowly warmed to -40 °C and stirred at this temperature for 1 hour. Upon completion of the reaction, the reaction was quenched with saturated NH4Cl solution (20 mL) and the cooling bath was removed. The reaction mixture was stirred overnight at room temperature. The precipitate was collected by filtration and dried under vacuum to give a tan solid product (9.5 g, 70% yield). lC/MS analysis showed m/z 171 [M+H]+ as a single component.

References

[1] Journal of Medicinal Chemistry, 2007, vol. 50, # 1, p. 2 - 5
[2] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 5, p. 1508 - 1511
[3] Patent: WO2006/113837, 2006, A2. Location in patent: Page/Page column 36; 62-63
[4] ACS Medicinal Chemistry Letters, 2015, vol. 6, # 1, p. 42 - 46
[5] Patent: WO2005/37197, 2005, A2. Location in patent: Page/Page column 94

5-NITRO-2-HYDROXY-4-METHOXYPYRIDINESupplier

J & K SCIENTIFIC LTD.
Tel
18210857532; 18210857532
Email
jkinfo@jkchemical.com
Shanghai Hanhong Scientific Co.,Ltd.
Tel
021-54306202 13764082696
Email
info@hanhongsci.com
ChemShuttle, Inc.
Tel
0510-83588313-811 18800520310
Email
sales@chemshuttle.com
Chiba Pharmaceutical Science and technology Co, Ltd.
Tel
0531-81313138 13066006660
Email
chibapharm@foxmail.com
Nanjing Norris-Pharm Technology Co., Ltd
Tel
18652989687
Email
sales@norris-pharm.com